An observational study in Type 2 Diabetes, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-10-18.
Sponsored by Boryung Pharmaceutical Co., Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Boryung Pharmaceutical Co., Ltd.
Among the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd, this one is one of 10 that started in 2024, is the only observational one, and was the 9th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 300 across 1,746 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 50 across the 13 interventional studies, 10,000 across the 1 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
2 of the studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT06649162Boryung Pharmaceutical Co., LtdA Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 2 by Boryung Pharmaceutical Co., Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score
Time frame: Baseline (visit 1)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 30 months is above that.
Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd →